Zhuoxing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhuoxing Li has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Xiang Xiao
Department of Nephrology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
2 shared publications - Buyuan Tian
Department of Nephrology First Affiliated Hospital of Chengdu Medical College Chengdu China
1 shared publication Hao Liu
Chengdu Medical College, China
1 shared publication- Hao Liu
Department of Clinical Medicine, Chengdu Medical College, Chengdu, China
1 shared publication Hui Gu
Chengdu Medical College, China
1 shared publicationMao Xiao
Chengdu Medical College, China
1 shared publication
Latest Publications
- 25 March 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Diet-microbiota-kidney axis reprogramming: mechanistic insights into microbial metabolite-driven precision nutrition for chronic kidney disease
Medical nutrition therapy serves as the cornerstone in the management of chronic kidney disease (CKD). While conventional approaches emphasize macronutrient restriction and meal timing adjustments, research highlights the critical mediating role of gut microbiota in translating dietary patterns into physiological effects through metabolite production. Meanwhile, CKD progression is closely associated with dynamic interactions between gut microbiota and their metabolic derivatives. This review introduces the "diet-microbiota- metabolite-kidney axis" framework to elucidate how nutritional components modulate CKD progression via microbial compositional changes and subsequent metabolite alterations. Based on synthesized evidence, this review identifies promising directions for precision nutrition strategies targeting microbial metabolites, including artificial intelligence-assisted dietary planning, engineered bacterial therapies, and metabolite analog development. However, significant interindividual variability in host genetics and baseline microbiota composition necessitates overcoming heterogeneity challenges in nutritional interventions. Consequently, the precise modulation of individualized diet-microbiota-metabolite interactions represents a critical research direction to be prioritized in CKD management.
- 25 March 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Diet-microbiota-kidney axis reprogramming: mechanistic insights into microbial metabolite-driven precision nutrition for chronic kidney disease
Medical nutrition therapy serves as the cornerstone in the management of chronic kidney disease (CKD). While conventional approaches emphasize macronutrient restriction and meal timing adjustments, research highlights the critical mediating role of gut microbiota in translating dietary patterns into physiological effects through metabolite production. Meanwhile, CKD progression is closely associated with dynamic interactions between gut microbiota and their metabolic derivatives. This review introduces the "diet-microbiota- metabolite-kidney axis" framework to elucidate how nutritional components modulate CKD progression via microbial compositional changes and subsequent metabolite alterations. Based on synthesized evidence, this review identifies promising directions for precision nutrition strategies targeting microbial metabolites, including artificial intelligence-assisted dietary planning, engineered bacterial therapies, and metabolite analog development. However, significant interindividual variability in host genetics and baseline microbiota composition necessitates overcoming heterogeneity challenges in nutritional interventions. Consequently, the precise modulation of individualized diet-microbiota-metabolite interactions represents a critical research direction to be prioritized in CKD management.
- Open Access
Osteoporosis Prevalence in Cardiovascular Kidney Metabolic Syndrome: Implications for Mortality
Objective: This study aims to investigate the prevalence of osteoporosis (OS) in patients with Cardiovascular Kidney Metabolic (CKM) Syndrome and its relationship with the risk of mortality in CKM patients. Methods: Patients diagnosed with CKM were included from the National Health and Nutrition Examination Survey database between 2009 and 2018. The primary endpoint was all-cause mortality, while the secondary endpoint was cardiovascular mortality. The relationship between OS and the prognosis of all-cause mortality and cardiovascular mortality in CKM patients was assessed using Kaplan-Meier survival curves and multivariate Cox regression model. Results: A total of 602 Non-CKM (stage 0) and 6129 CKM (stages 1, 2, 3, and 4) patients were included. The prevalence of OS in CKM patients at stages 0, 1, 2, 3, and 4 was 3.49%, 2.25%, 4.97%, 13.52%, and 8.39%, respectively. The multivariate Cox regression analysis revealed that compared to the normal bone mineral density group, CKM patients in the osteopenia group had a 55% increased risk of all-cause mortality (HR=1.55; 95% CI, 1.22-1.98, P = 0.001) and a 120% increase in the risk of cardiovascular mortality (HR=2.20; 95% CI, 1.39-3.46, P = 0.001); In the OS group, CKM patients exhibited a 199% increased risk of all-cause mortality (HR = 2.99; 95% CI, 1.86-4.82, P = 0.001) and a 2.14-fold increase in the risk of cardiovascular mortality (HR=3.14; 95% CI, 1.09-9.02, P = 0.03). Conclusion: Osteopenia and OS are more prevalent in patients with CKM and are associated with an increased risk of all-cause and cardiovascular mortality.
Open AccessOsteoporosis Prevalence in Cardiovascular Kidney Metabolic Syndrome: Implications for Mortality
Objective: This study aims to investigate the prevalence of osteoporosis (OS) in patients with Cardiovascular Kidney Metabolic (CKM) Syndrome and its relationship with the risk of mortality in CKM patients. Methods: Patients diagnosed with CKM were included from the National Health and Nutrition Examination Survey database between 2009 and 2018. The primary endpoint was all-cause mortality, while the secondary endpoint was cardiovascular mortality. The relationship between OS and the prognosis of all-cause mortality and cardiovascular mortality in CKM patients was assessed using Kaplan-Meier survival curves and multivariate Cox regression model. Results: A total of 602 Non-CKM (stage 0) and 6129 CKM (stages 1, 2, 3, and 4) patients were included. The prevalence of OS in CKM patients at stages 0, 1, 2, 3, and 4 was 3.49%, 2.25%, 4.97%, 13.52%, and 8.39%, respectively. The multivariate Cox regression analysis revealed that compared to the normal bone mineral density group, CKM patients in the osteopenia group had a 55% increased risk of all-cause mortality (HR=1.55; 95% CI, 1.22-1.98, P = 0.001) and a 120% increase in the risk of cardiovascular mortality (HR=2.20; 95% CI, 1.39-3.46, P = 0.001); In the OS group, CKM patients exhibited a 199% increased risk of all-cause mortality (HR = 2.99; 95% CI, 1.86-4.82, P = 0.001) and a 2.14-fold increase in the risk of cardiovascular mortality (HR=3.14; 95% CI, 1.09-9.02, P = 0.03). Conclusion: Osteopenia and OS are more prevalent in patients with CKM and are associated with an increased risk of all-cause and cardiovascular mortality.